Loading…
Insmed Incorporated is projected to rise to $151.05 by 2027, a +42% move from its current price of $106.40. INSM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $102.93 | $106.41 | $110.00 | +0.01% |
| May 30 | $101.53 | $106.41 | $111.53 | +0.01% |
| May 31 | $100.47 | $106.42 | $112.71 | +0.02% |
| Jun 1 | $99.59 | $106.42 | $113.73 | +0.02% |
| Jun 2 | $98.82 | $106.43 | $114.63 | +0.03% |
| Jun 3 | $98.13 | $106.44 | $115.45 | +0.03% |
| Jun 4 | $97.49 | $106.44 | $116.21 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $97.49 | $106.44 | $116.21 | +0.04% |
| Week 2 | $94.05 | $106.49 | $120.56 | +0.08% |
| Week 3 | $91.50 | $106.53 | $124.03 | +0.12% |
| Week 4 | $89.41 | $106.57 | $127.03 | +0.16% |
| Week 5 | $87.61 | $106.61 | $129.74 | +0.20% |
| Week 6 | $86.01 | $106.66 | $132.25 | +0.24% |
| Week 7 | $84.58 | $106.70 | $134.60 | +0.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, and it is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. The organization is also developing brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1) that is in phase 3 for bronchiectasis; and in phase 2 for chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.
In addition, Insmed is advancing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug, which is in phase 3 for the treatment of pulmonary hypertension associated with interstitial lung disease and in phase 2 for pulmonary arterial hypertension. The company is also developing INS1201, a microdystrophin adeno-associated virus gene replacement therapy in phase 1 for Duchenne muscular dystrophy, along with pre-clinical programs in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. It provides INS1148, a monoclonal antibody targeting stem cell factor (SCF248) in phase-2 for interstitial lung disease and asthma, and INS1202, an intrathecally delivered gene therapy in phase 1 for amyotrophic lateral sclerosis.
The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed Incorporated (INSM) trades in the healthcare space with a focus on therapies for serious and rare diseases across major regions. The stock currently sits at $106.24 per share, with a market capitalization of $23.03B and a market-position ranking of 527. The long-term forecast indicates meaningful upside, with average prices rising from $106.24 in 2026 to higher levels through 2050 and a max forecast extending into the hundreds of dollars per share.
A major floor 31.6% below — a decisive break under it would weaken the trend.
The nearest floor, 4.7% below — buyers have tended to step in here.
The nearest ceiling, 37.9% above — a clean break opens room to run.
A major ceiling 55.0% above — clearing it would confirm fresh momentum.
Key INSM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INSM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $107.79 | Sell | $107.81 | Sell |
| MA 10 | $109.63 | Sell | $110.11 | Sell |
| MA 20 | $117.18 | Sell | $116.72 | Sell |
| MA 50 | $135.94 | Sell | $130.60 | Sell |
| MA 100 | $145.67 | Sell | $141.05 | Sell |
| MA 200 | $155.97 | Sell | $140.41 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.00 | Neutral |
| Stoch RSI (14) | 78.76 | Neutral |
| CCI (20) | -60.48 | Neutral |
| Williams %R (14) | -69.65 | Info |
| MACD (12,26,9) | 0.18 | Buy |
| ROC (12) | 4.98 | Buy |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 30.35 | Neutral |
| TRIX (15) | -1.02 | Sell |
| Awesome (5,34) | -20.88 | Sell |
| Ultimate (7,14,28) | 35.53 | Neutral |
| Momentum (10) | -9.60 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 107.10 | Sell |
| ADX (14) | 28.03 | Sell |
| ATR (14) | 3.71 | Info |
The 30-day technical picture shows a bearish tilt. RSI(14) is 30, indicating oversold conditions relative to recent activity. The stock trades below the 50-day simple moving average of $137.31 and below the 200-day simple moving average of $155.99, suggesting near-term weakness.
Support is noted at $101.35 and resistance at $153.40, with a 30-day price range from $84.57 to $133.46, and annualized volatility at 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $101.35 | $106.40 | $147.97 | 0% | Neutral | |
| $117.29 | $151.05 | $207.48 | +42% | Bullish | |
| $123.51 | $164.52 | $235.69 | +55% | Bullish | |
| $122.36 | $167.69 | $248.31 | +58% | Bullish | |
| $130.30 | $183.18 | $278.91 | +72% | Bullish | |
| $127.02 | $182.77 | $285.15 | +72% | Bullish | |
| $142.97 | $210.27 | $335.27 | +98% | Bullish | |
| $174.14 | $261.45 | $425.17 | +146% | Bullish | |
| $179.52 | $274.90 | $455.20 | +158% | Bullish | |
| $200.89 | $313.52 | $527.95 | +195% | Bullish | |
| $261.50 | $445.28 | $804.29 | +319% | Bullish | |
| $378.34 | $752.18 | $1,503.50 | +607% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $101.35 | $106.40 | $126.06 | +0.00% |
| June 2026 | $92.74 | $109.43 | $132.57 | +2.85% |
| July 2026 | $89.72 | $106.96 | $131.69 | -2.26% |
| August 2026 | $90.01 | $108.17 | $134.85 | +1.14% |
| September 2026 | $92.29 | $111.65 | $140.60 | +3.22% |
| October 2026 | $90.49 | $110.16 | $139.99 | -1.34% |
| November 2026 | $88.96 | $108.87 | $139.46 | -1.17% |
| December 2026 | $93.19 | $114.65 | $147.97 | +5.31% |
Click any year to see its month-by-month INSM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Insmed Incorporated's 2026 outlook centres on $106.40, within a $101.35 to $147.97 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, INSM could reach as high as $207.48, with a base case around $151.05 and support toward $117.29 — roughly +42% from $106.40. Buyers look set to stay in control over this stretch.
Expect INSM to range from $123.51 to $235.69 through 2028. The $164.52 average target implies a +55% move from current prices. That is up +9% on the projected 2027 average. Momentum favours further upside here.
The INSM price prediction for 2029 points to an average of $167.69 (low $122.36, high $248.31) — a potential gain of +58% on today's $106.40. Buyers look set to stay in control over this stretch.
In 2030, INSM is projected to trade between $130.30 and $278.91, averaging $183.18 — a potential gain of +72% from today's $106.40. That is up +9% on the projected 2029 average. Momentum favours further upside here.
Insmed Incorporated's 2031 outlook centres on $182.77, within a $127.02 to $285.15 range. That is 0% versus the projected 2030 average. That marks a +72% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, INSM could reach as high as $335.27, with a base case around $210.27 and support toward $142.97 — roughly +98% from $106.40. Momentum favours further upside here.
Expect INSM to range from $174.14 to $425.17 through 2033. The $261.45 average target implies a +146% move from current prices. That is up +24% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The INSM price prediction for 2034 points to an average of $274.90 (low $179.52, high $455.20) — a potential gain of +158% on today's $106.40. Momentum favours further upside here.
In 2035, INSM is projected to trade between $200.89 and $527.95, averaging $313.52 — a potential gain of +195% from today's $106.40. That is up +14% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Insmed Incorporated's 2040 outlook centres on $445.28, within a $261.50 to $804.29 range. That is up +42% on the projected 2035 average. That marks a +319% change versus current levels. Momentum favours further upside here.
By 2050, INSM could reach as high as $1,503.50, with a base case around $752.18 and support toward $378.34 — roughly +607% from $106.40. Buyers look set to stay in control over this stretch.
Investing $1,000 in INSM today (≈ 9.398496 INSM) could be worth
$7,069.34
+$6,069.34 (+607%) by 2050 · US Dollar
Based on the average projected INSM price of $752.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INSMwould be worth at today's price.
$1,000 invested in INSM on May 27, 2025 (≈ 14.701559 INSM) would be worth
$1,564.25
+$564.25 (+56.4%) today · 1.56× · US Dollar
Based on a INSM entry price of $68.02 vs. today's $106.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $107.91 | $986.01 | -1.4% |
| 1 month ago | $135.98 | $782.47 | -21.8% |
| 3 months ago | $150 | $709.33 | -29.1% |
| 6 months ago | $207.77 | $512.1 | -48.8% |
| 1 year ago | $68.02 | $1,564.25 | +56.4% |
| All time (5.0y) ago | $25.17 | $4,227.25 | +322.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INSM forecast.
Our base-case forecast reaches $210.00 around 2032.
Implied market cap at $210.00: $45.52B
The year-by-year forecast paints a bullish multi-year trajectory after a neutral start in 2026. For 2026, the average price is $106.24 with a max of $149.90 and a min of $101.35, delivering 0% ROI. In 2027 the forecast shows an average of $150.85 (min $116.47, max $208.74) with a 42% ROI and a bullish sentiment.
By 2028 the average is $164.41 (min $122.53, max $237.57) with a 54.8% ROI, and 2029 shows an average of $167.10 (min $120.88, max $249.84) with a 57.3% ROI. The 2030 forecast moves to an average of $180.46 (min $127.10, max $277.67) and a 69.9% ROI, continuing bullish momentum into 2031 (avg $180.49, min $124.04, max $284.76, ROI 69.9%). The trajectory strengthens further through 2032–2035 (avg $207.67, $256.63, $271.32; ROI 95.5%, 141.6%, 155.4%), and 2035 shows an average of $310.84 with a max of $530.51 and a 192.6% ROI.
The forecast then accelerates markedly in later years, with 2040 an average of $435.67 and a max of $799.08 (ROI 310.1%), and 2050 an average of $735.24 and a max of $1,496.12 (ROI 592.1%), all described with bullish sentiment. These figures illustrate an upside path over the long term, balanced by the inherent uncertainty of price forecasts.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $180.46 with a min of $127.10, a max of $277.67 and a ROI of 69.9%, with a bullish sentiment.
The outlook shifts from neutral in 2026 (avg $106.24, ROI 0%) to bullish from 2027 onward, with average prices rising to $180.46 by 2030 and up to $735.24 by 2050, and a peak max forecast of $1,496.12 in 2050 (ROI 592.1%). These are estimates, not guarantees.
Yes, the forecast shows max values above $500: $530.51 in 2035, $799.08 in 2040, and $1,496.12 in 2050, with the average rising to $310.84 by 2035 and $735.24 by 2050.
Current price is $106.24 per share and market capitalization is $23.03B.
Bearish sentiment with RSI(14) at 30. The 30-day range runs from $84.57 to $133.46, with the 50-day SMA at $137.31 and the 200-day SMA at $155.99. Support is at $101.35 and resistance at $153.40, and annualized volatility is 70%.
Insmed Incorporated Community Discussion
0Share your Insmed Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.